CTOs on the Move

INmuneBIO

www.inmunebio.com

 
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient`s immune system to treat cancer. INKmune, the company`s lead product, primes patient`s NK cells (natural killer cells) to kill cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.inmunebio.com
  • 1200 Prospect Street Suite 525
    La Jolla, CA USA 92037
  • Phone: 858.964.3720

Executives

Name Title Contact Details

Funding

INmuneBIO raised $25M on 07/20/2020
INmuneBIO raised $15M on 06/14/2021

Similar Companies

Cresilon Inc

Recognizing the importance of managing a traumatic bleed quickly and effectively, Joe Landolina and Isaac Miller founded Cresilon, Inc. based on the hemostatic plant-based gel technology Joe invented while experimenting in the lab. Cresilon has since grown into a biotechnology company headquartered in Brooklyn, New York, commercializing our medical device technology in the animal health, trauma care, and surgical markets.

EnviroLogix

Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.

Future Family

Future Family is where women, men and couples start their fertility journey. The company`s mission is to make fertility care accessible and affordable to all.

Asterias Biotherapeutics

Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.

Camurus

Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner. New drug products with best-in-class potential are conceived based on the companys proprietary FluidCrystal® technology and extensive R&D expertise. Camurus clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies. The companys shares are listed on Nasdaq Stockholm under the ticker CAMX.